Multiplikator Forward P/S GRAIL, Inc. (GRAL)

GRAL (GRAIL Bio) - tandha merek perusahaan

GRAIL, Inc. is advancing cancer diagnostics through partnerships with clinics and insurers. The company is engaged in a fierce battle for leadership in the liquid biopsy sector. This GURU.Markets chart, which serves as a forward P/S indicator, shows that the latest reading is 32.60. The business is currently focusing on expanding its operations and securing insurance reimbursements for its innovative tests.

GRAL grail.com: Rasio kapitalisasi marang dodolan sing dikarepake ing interval 15.11.2024 - 13.11.2026

Rincian metrik komprehensif lan analitis GRAIL Bio (GRAL)

- rega pasar lan target rega analis:
Bagan rega GRAIL|GRAL - Target median analis
- rincian kapitalisasi pasar:
Kapitalisasi pasar GRAIL Bio|GRAL - Rega Tumbas Perusahaan
- statistik nilai buku emiten:
Aset Bersih saben Siji Saham GRAIL|GRAL - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku grail.com|GRAL - Aset Neraca Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas GRAIL, Inc.|GRAL - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal GRAIL, Inc.|GRAL - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku GRAIL Bio|GRAL - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan GRAIL|Indikator likuiditas cepet grail.com
- data bathi bisnis lan rasio investasi:
GRAL - Bathi pungkasan|Proyeksi bathi mangsa ngarep GRAIL, Inc.|GRAL - Periode bali modal bisnis|Rega marang bathi mangsa ngarep GRAIL Corp|GRAL - Rasio P/E diaturake wutah|Pangali EV/EBITDA GRAIL Bio|GRAL - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan GRAIL|GRAL - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan grail.com|GRAL - Owah-owahan bathi resik saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep GRAIL, Inc.
- indikator volume dodolan lan pendapatan:
GRAL - Pendapatan dodolan perusahaan|Prakiraan volume dodolan GRAIL|GRAL - Multiplikator P/S|Rasio rega marang prakiraan pendapatan GRAIL Bio
Analisis fundamental perusahaan:GRAIL GRAL
Produk asli GRAIL Bio

Challenges with cancer diagnostic reimbursement and high marketing expenses are creating revenue uncertainty for GRAIL, Inc. (GRAL). This chart of the company's expected P/S ratio visualizes the relationship between current market capitalization and projected revenue. An increase in this indicator signals an exuberant overpayment, where the market price outpaces actual sales growth. A sharp decline in the metric should the company fail to meet revenue targets will trigger a rapid devaluation of the shares.

Analisis perusahaan pesaing

Rasio rega marang prakiraan pendapatan Caris Life Sciences CAI|Rasio kapitalisasi marang dodolan sing dikarepake Guardant Health Inc (GH)|Veracyte Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Celcuity Therapeutics CELC|Myriad Genetics, Inc. (MYGN) - Rasio rega marang prakiraan pendapatan|CSTL - Rasio kapitalisasi marang dodolan sing dikarepake|BNR (Burning Rock) - Multiplikator Forward P/S|VNRX - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Biodesix Corp (BDSX)|PRPO (Precipio Inc) - Rega forward marang dodolan|Multiplikator Forward P/S CHEK (Check-Cap)|Multiplikator Forward P/S Mainz Biomed NV MYNZ|OncoCyte - Multiplikator Forward P/S